ATE452188T1 - Rna-interferenz-vermittelte hemmung der genexpression unter verwendung multifunktioneller sina (short interfering nucleic acid) - Google Patents
Rna-interferenz-vermittelte hemmung der genexpression unter verwendung multifunktioneller sina (short interfering nucleic acid)Info
- Publication number
- ATE452188T1 ATE452188T1 AT05713300T AT05713300T ATE452188T1 AT E452188 T1 ATE452188 T1 AT E452188T1 AT 05713300 T AT05713300 T AT 05713300T AT 05713300 T AT05713300 T AT 05713300T AT E452188 T1 ATE452188 T1 AT E452188T1
- Authority
- AT
- Austria
- Prior art keywords
- nucleic acid
- multifunctional sina
- gene expression
- short interfering
- molecules
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1131—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1136—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against growth factors, growth regulators, cytokines, lymphokines or hormones
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
- C12N2310/111—Antisense spanning the whole gene, or a large part of it
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/351—Conjugate
- C12N2310/3519—Fusion with another nucleic acid
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/50—Physical structure
- C12N2310/51—Physical structure in polymeric form, e.g. multimers, concatemers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/50—Physical structure
- C12N2310/53—Physical structure partially self-complementary or closed
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- General Health & Medical Sciences (AREA)
- Biophysics (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Biochemistry (AREA)
- Physics & Mathematics (AREA)
- Endocrinology (AREA)
- Virology (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US54348004P | 2004-02-10 | 2004-02-10 | |
| PCT/US2004/016390 WO2005019453A2 (en) | 2001-05-18 | 2004-05-24 | RNA INTERFERENCE MEDIATED INHIBITION OF GENE EXPRESSION USING CHEMICALLY MODIFIED SHORT INTERFERING NUCLEIC ACID (siNA) |
| PCT/US2005/004270 WO2005078097A2 (en) | 2004-02-10 | 2005-02-09 | RNA INTERFERENCE MEDIATED INHIBITION OF GENE EXPRESSION USING MULTIFUNCTIONAL SHORT INTERFERING NUCLEIC ACID (Multifunctional siNA) |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE452188T1 true ATE452188T1 (de) | 2010-01-15 |
Family
ID=56290660
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT05713300T ATE452188T1 (de) | 2004-02-10 | 2005-02-09 | Rna-interferenz-vermittelte hemmung der genexpression unter verwendung multifunktioneller sina (short interfering nucleic acid) |
Country Status (7)
| Country | Link |
|---|---|
| US (2) | US7858769B2 (de) |
| EP (1) | EP1713915B1 (de) |
| JP (1) | JP2007523649A (de) |
| AT (1) | ATE452188T1 (de) |
| AU (1) | AU2005212433B2 (de) |
| CA (1) | CA2554212A1 (de) |
| WO (1) | WO2005078097A2 (de) |
Families Citing this family (140)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9994853B2 (en) | 2001-05-18 | 2018-06-12 | Sirna Therapeutics, Inc. | Chemically modified multifunctional short interfering nucleic acid molecules that mediate RNA interference |
| US7517864B2 (en) * | 2001-05-18 | 2009-04-14 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of vascular endothelial growth factor and vascular endothelial growth factor receptor gene expression using short interfering nucleic acid (siNA) |
| US9181551B2 (en) | 2002-02-20 | 2015-11-10 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA) |
| US9657294B2 (en) | 2002-02-20 | 2017-05-23 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA) |
| US20080207542A1 (en) * | 2002-03-26 | 2008-08-28 | Sirna Therapeutics, Inc. | RNA inteference mediated inhibition of hepatitis C virus (HVC) gene expression using short interfering nucleic acid (siNA) |
| WO2005105995A2 (en) * | 2004-04-14 | 2005-11-10 | Sirna Therapeutics, Inc. | RNA INTERFERENCE MEDIATED TREATMENT OF POLYGLUTAMINE (POLYQ) REPEAT EXPANSION DISEASES USING SHORT INTERFERING NUCLEIC ACID (siNA) |
| US10508277B2 (en) | 2004-05-24 | 2019-12-17 | Sirna Therapeutics, Inc. | Chemically modified multifunctional short interfering nucleic acid molecules that mediate RNA interference |
| JP2009520039A (ja) * | 2005-12-19 | 2009-05-21 | サーナ・セラピューティクス・インコーポレイテッド | 低分子干渉核酸（ｓｉＮＡ）を用いた、ＲＮＡ干渉によって媒介される、Ｃ型肝炎ウイルス（ＨＣＶ）遺伝子発現の阻害 |
| WO2007147067A2 (en) | 2006-06-14 | 2007-12-21 | Rosetta Inpharmatics Llc | Methods and compositions for regulating cell cycle progression |
| WO2008109361A1 (en) * | 2007-03-02 | 2008-09-12 | Mdrna, Inc, | Nucleic acid compounds for inhibiting erbb family gene expression and uses thereof |
| JP2010519907A (ja) * | 2007-03-02 | 2010-06-10 | エムディーアールエヌエー，インコーポレイテッド | Ｖｅｇｆファミリー遺伝子の発現を抑制するための核酸化合物およびその使用 |
| US11078262B2 (en) | 2007-04-30 | 2021-08-03 | Allergan, Inc. | High viscosity macromolecular compositions for treating ocular conditions |
| US8399248B2 (en) | 2007-05-03 | 2013-03-19 | Merck Sharp & Dohme Corp. | Methods of using MIR34 as a biomarker for TP53 functional status |
| WO2009045457A2 (en) * | 2007-10-02 | 2009-04-09 | Rxi Pharmaceuticals Corp. | Tripartite rnai constructs |
| WO2011046934A1 (en) * | 2009-10-12 | 2011-04-21 | Au Jessie L-S | Methods and compositions for improved delivery, expression or activity of rna interference agents |
| JP6106085B2 (ja) | 2010-08-24 | 2017-03-29 | サーナ・セラピューティクス・インコーポレイテッドＳｉｒｎａ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． | 内部非核酸スペーサーを含む一本鎖ＲＮＡｉ剤 |
| KR101223484B1 (ko) * | 2010-10-05 | 2013-01-17 | 한국과학기술연구원 | 사람 혈청 알부민-ｓｉＲＮＡ 나노입자 전달체 |
| WO2012058210A1 (en) | 2010-10-29 | 2012-05-03 | Merck Sharp & Dohme Corp. | RNA INTERFERENCE MEDIATED INHIBITION OF GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACIDS (siNA) |
| DE102011009470A1 (de) * | 2011-01-21 | 2012-08-09 | Friedrich-Schiller-Universität Jena | Biologisch wirksame Nukleotid-Moleküle zur gezielten Abtötung von Zellen, Verwendung derselben sowie Applikationskit |
| UA118649C2 (uk) | 2011-11-18 | 2019-02-25 | Елнілем Фармасьютікалз, Інк. | ДВОЛАНЦЮГОВИЙ ЗАСІБ ДЛЯ PHKі ТА ФАРМАЦЕВТИЧНА КОМПОЗИЦІЯ ДЛЯ ІНГІБУВАННЯ ЕКСПРЕСІЇ ТРАНСТИРЕТИНУ (TTR) |
| US9796974B2 (en) | 2011-11-18 | 2017-10-24 | Alnylam Pharmaceuticals, Inc. | Modified RNAi agents |
| AU2013296321B2 (en) | 2012-08-03 | 2019-05-16 | Alnylam Pharmaceuticals, Inc. | Modified RNAi agents |
| BR112015013105B1 (pt) | 2012-12-05 | 2022-02-08 | Alnylam Pharmaceuticals, Inc | Agente de rnai de fita dupla capaz de inibir a expressão de pcsk9, seus usos, composição farmacêutica e método de inibição da expressão de pcsk9 em uma célula in vitro |
| PT2970974T (pt) | 2013-03-14 | 2017-11-29 | Alnylam Pharmaceuticals Inc | Composições de irna de componente do complemento c5 e métodos para a sua utilização |
| AU2014268529C1 (en) | 2013-05-22 | 2020-10-01 | Alnylam Pharmaceuticals, Inc. | TMPRSS6 iRNA compositions and methods of use thereof |
| TWI664187B (zh) | 2013-05-22 | 2019-07-01 | 阿尼拉製藥公司 | 絲胺酸蛋白酶抑制因子Ａ１ ｉＲＮＡ組成物及其使用方法 |
| WO2015042564A1 (en) | 2013-09-23 | 2015-03-26 | Alnylam Pharmaceuticals, Inc. | Methods for treating or preventing transthyretin (ttr) associated diseases |
| WO2015089368A2 (en) | 2013-12-12 | 2015-06-18 | Alnylam Pharmaceuticals, Inc. | Complement component irna compositions and methods of use thereof |
| WO2015106128A2 (en) | 2014-01-09 | 2015-07-16 | Alnylam Pharmaceuticals, Inc. | MODIFIED RNAi AGENTS |
| EP3105331B1 (de) | 2014-02-11 | 2021-06-23 | Alnylam Pharmaceuticals, Inc. | Ketohexokinase (khk)-irna-zusammensetzungen und verfahren zur verwendung davon |
| TW201607559A (zh) | 2014-05-12 | 2016-03-01 | 阿尼拉製藥公司 | 治療ｓｅｒｐｉｎｃ１相關疾患之方法和組成物 |
| SG11201609376SA (en) | 2014-05-22 | 2016-12-29 | Alnylam Pharmaceuticals Inc | Angiotensinogen (agt) irna compositions and methods of use thereof |
| IL316808A (en) | 2014-08-20 | 2025-01-01 | Alnylam Pharmaceuticals Inc | Modified double-stranded RNA materials and their uses |
| TWI864340B (zh) | 2014-10-10 | 2024-12-01 | 美商艾爾妮蘭製藥公司 | 用於抑制hao1(羥酸氧化酶1(乙醇酸鹽氧化酶))基因表現的組合物及方法 |
| TWI769565B (zh) | 2014-11-10 | 2022-07-01 | 美商阿尼拉製藥公司 | Ｂ型肝炎病毒（ＨＢＶ）ｉＲＮＡ組成物及其用途方法 |
| WO2016081444A1 (en) | 2014-11-17 | 2016-05-26 | Alnylam Pharmaceuticals, Inc. | Apolipoprotein c3 (apoc3) irna compositions and methods of use thereof |
| US20170369872A1 (en) | 2014-12-18 | 2017-12-28 | Alnylam Pharmaceuticals, Inc. | Reversir tm compounds |
| JP2018510621A (ja) | 2015-02-13 | 2018-04-19 | アルナイラム ファーマシューティカルズ， インコーポレイテッドＡｌｎｙｌａｍ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． | パタチン様ホスホリパーゼドメイン含有３（ＰＮＰＬＡ３）ｉＲＮＡ組成物およびその使用方法 |
| EP3307316A1 (de) | 2015-06-12 | 2018-04-18 | Alnylam Pharmaceuticals, Inc. | Gegen komplementkomponente c5 gerichtete irna-zusammensetzungen und verfahren zur verwendung davon |
| US10494632B2 (en) | 2015-07-10 | 2019-12-03 | Alnylam Pharmaceuticals, Inc. | Insulin-like growth factor binding protein, acid labile subunit (IGFALS) compositions and methods of use thereof |
| CA3205381A1 (en) * | 2015-07-17 | 2017-01-26 | Alnylam Pharmaceuticals, Inc. | Multi-targeted single entity conjugates |
| US10889813B2 (en) | 2015-09-02 | 2021-01-12 | Alnylam Pharmaceuticals, Inc. | Programmed cell death 1 ligand 1 (PD-L1) iRNA compositions and methods of use thereof |
| IL308717A (en) | 2015-12-07 | 2024-01-01 | Genzyme Corp | Methods and compositions for treating a serpinc1-associated disorder |
| EP3469083A1 (de) | 2016-06-10 | 2019-04-17 | Alnylam Pharmaceuticals, Inc. | Gegen komplementkomponente c5 gerichtete irna-zusammensetzungen und verfahren zur verwendung davon zur behandlung von paroxysmaler nächtlicher hämoglobinurie (pnh) |
| TW202313978A (zh) | 2016-11-23 | 2023-04-01 | 美商阿尼拉製藥公司 | 絲胺酸蛋白酶抑制因子Ａ１ ｉＲＮＡ組成物及其使用方法 |
| US20180193270A1 (en) | 2016-11-29 | 2018-07-12 | PureTech Health LLC | Exosomes for delivery of therapeutic agents |
| TWI865997B (zh) | 2016-12-16 | 2024-12-11 | 美商阿尼拉製藥公司 | 使用甲狀腺素運載蛋白（ＴＴＲ）ｉＲＮＡ組成物於治療或預防ＴＴＲ相關疾病之方法 |
| JP2020530442A (ja) | 2017-07-10 | 2020-10-22 | ジェンザイム・コーポレーション | 血友病を有する対象の出血事象を処置するための方法および組成物 |
| AU2018301829B2 (en) | 2017-07-13 | 2024-08-01 | Alnylam Pharmaceuticals, Inc. | Methods for inhibition of HAO1 (hydroxyacid oxidase 1 (glycolate oxidase) gene expression |
| CA3069868A1 (en) | 2017-07-13 | 2019-01-17 | Alnylam Pharmaceuticals Inc. | Lactate dehydrogenase a (ldha) irna compositions and methods of use thereof |
| EP3710587A1 (de) | 2017-11-16 | 2020-09-23 | Alnylam Pharmaceuticals, Inc. | Apolipoprotein-c3 kisspeptin 1 (kiss1)-irna-zusammensetzungen und verfahren zur verwendung davon |
| WO2019100039A1 (en) | 2017-11-20 | 2019-05-23 | Alnylam Pharmaceuticals, Inc. | Serum amyloid p component (apcs) irna compositions and methods of use thereof |
| WO2019126097A1 (en) | 2017-12-18 | 2019-06-27 | Alnylam Pharmaceuticals, Inc. | High mobility group box-1 (hmgb1) irna compositions and methods of use thereof |
| CA3098623A1 (en) | 2018-05-07 | 2019-11-14 | Alnylam Pharmaceuticals, Inc. | Extrahepatic delivery |
| TWI851574B (zh) | 2018-05-14 | 2024-08-11 | 美商阿尼拉製藥公司 | 血管收縮素原（ＡＧＴ）ｉＲＮＡ組成物及其使用方法 |
| JP2022500003A (ja) | 2018-09-18 | 2022-01-04 | アルナイラム ファーマシューティカルズ, インコーポレイテッドAlnylam Pharmaceuticals, Inc. | ケトヘキソキナーゼ（ＫＨＫ）ｉＲＮＡ組成物およびその使用方法 |
| CA3114396A1 (en) | 2018-09-28 | 2020-04-02 | Alnylam Pharmaceuticals, Inc. | Transthyretin (ttr) irna compositions and methods of use thereof for treating or preventing ttr-associated ocular diseases |
| WO2020236600A1 (en) | 2019-05-17 | 2020-11-26 | Alnylam Pharmaceuticals, Inc. | Oral delivery of oligonucleotides |
| EP4007812A1 (de) | 2019-08-01 | 2022-06-08 | Alnylam Pharmaceuticals, Inc. | Irna-zusammensetzungen der serpinfamilie f element 2 (serpinf2) und verfahren zu deren verwendung |
| WO2021022108A2 (en) | 2019-08-01 | 2021-02-04 | Alnylam Pharmaceuticals, Inc. | CARBOXYPEPTIDASE B2 (CPB2) iRNA COMPOSITIONS AND METHODS OF USE THEREOF |
| WO2021030522A1 (en) | 2019-08-13 | 2021-02-18 | Alnylam Pharmaceuticals, Inc. | SMALL RIBOSOMAL PROTEIN SUBUNIT 25 (RPS25) iRNA AGENT COMPOSITIONS AND METHODS OF USE THEREOF |
| US12503699B2 (en) | 2019-10-04 | 2025-12-23 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for silencing UGT1a1 gene expression |
| EP4045652A1 (de) | 2019-10-18 | 2022-08-24 | Alnylam Pharmaceuticals, Inc. | Irna-zusammensetzungen eines elements der solute-carrier-familie und verwendungsverfahren dafür |
| CA3158320A1 (en) | 2019-10-22 | 2021-04-29 | Alnylam Pharmaceuticals, Inc. | Complement component c3 irna compositions and methods of use thereof |
| WO2021087036A1 (en) | 2019-11-01 | 2021-05-06 | Alnylam Pharmaceuticals, Inc. | HUNTINGTIN (HTT) iRNA AGENT COMPOSITIONS AND METHODS OF USE THEREOF |
| US20230040920A1 (en) | 2019-11-01 | 2023-02-09 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for silencing dnajb1-prkaca fusion gene expression |
| EP4055165A1 (de) | 2019-11-06 | 2022-09-14 | Alnylam Pharmaceuticals, Inc. | Transthyretin (ttr)-irna-zusammensetzungen und verfahren zur verwendung davon für die behandlung oder prävention ttr-assoziierter augenerkrankungen |
| WO2021092371A2 (en) | 2019-11-06 | 2021-05-14 | Alnylam Pharmaceuticals, Inc. | Extrahepatic delivery |
| IL292865A (en) | 2019-11-13 | 2022-07-01 | Alnylam Pharmaceuticals Inc | Methods and preparations for the treatment of angiotensinogen-related disorder - (agt) |
| EP4061945A1 (de) | 2019-11-22 | 2022-09-28 | Alnylam Pharmaceuticals, Inc. | Ataxin3 (atxn3)-rnai-wirkstoffzusammensetzungen und verfahren zu deren verwendung |
| IL293824A (en) | 2019-12-13 | 2022-08-01 | Alnylam Pharmaceuticals Inc | Compositions of RNA material (c9orf72) human chromosome 9 open reading frame 72 and methods of using them |
| CN115176007A (zh) | 2019-12-16 | 2022-10-11 | 阿尔尼拉姆医药品有限公司 | 含类PATATIN磷脂酶结构域3(PNPLA3)iRNA组合物及其使用方法 |
| WO2021154941A1 (en) | 2020-01-31 | 2021-08-05 | Alnylam Pharmaceuticals, Inc. | Complement component c5 irna compositions for use in the treatment of amyotrophic lateral sclerosis (als) |
| PH12022552080A1 (en) | 2020-02-10 | 2024-02-12 | Alnylam Pharmaceuticals Inc | Compositions and methods for silencing vegf-a expression |
| CN115397989A (zh) | 2020-02-18 | 2022-11-25 | 阿尔尼拉姆医药品有限公司 | 载脂蛋白C3(APOC3)iRNA组合物及其使用方法 |
| EP4114947A1 (de) | 2020-03-05 | 2023-01-11 | Alnylam Pharmaceuticals, Inc. | Komplementkomponenten-c3-irna-zusammensetzungen und verfahren zur verwendung davon zur behandlung oder prävention von mit komplementkomponenten-c3-assoziierten erkrankungen |
| MX2022011009A (es) | 2020-03-06 | 2022-10-07 | Alnylam Pharmaceuticals Inc | Composiciones de acido ribonucleico de interferencia (arni) de ketohexocinasa (khk) y metodos de uso de las mismas. |
| EP4121534A1 (de) | 2020-03-18 | 2023-01-25 | Alnylam Pharmaceuticals, Inc. | Zusammensetzungen und verfahren zur behandlung von patienten mit einer heterozygoten alaninglyoxylat-aminotransferase-genvariante (agxt) |
| WO2021195307A1 (en) | 2020-03-26 | 2021-09-30 | Alnylam Pharmaceuticals, Inc. | Coronavirus irna compositions and methods of use thereof |
| US20230190785A1 (en) | 2020-03-30 | 2023-06-22 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for silencing dnajc15 gene expression |
| EP4127134A4 (de) | 2020-04-01 | 2024-07-31 | Alnylam Pharmaceuticals, Inc. | Irna-wirkstoffzusammensetzungen mit alpha-2a-adrenergen rezeptor (adra2a) und verfahren zur verwendung davon |
| IL297121A (en) | 2020-04-06 | 2022-12-01 | Alnylam Pharmaceuticals Inc | Compositions and methods for silencing myoc expression |
| EP4133077A1 (de) | 2020-04-07 | 2023-02-15 | Alnylam Pharmaceuticals, Inc. | Irna-zusammensetzungen mit transmembran-serinprotease 2 (tmprss2) und verfahren zur verwendung davon |
| AU2021251754A1 (en) | 2020-04-07 | 2022-11-03 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for silencing SCN9A expression |
| WO2021206917A1 (en) | 2020-04-07 | 2021-10-14 | Alnylam Pharmaceuticals, Inc. | ANGIOTENSIN-CONVERTING ENZYME 2 (ACE2) iRNA COMPOSITIONS AND METHODS OF USE THEREOF |
| JP7844347B2 (ja) | 2020-04-27 | 2026-04-13 | アルナイラム ファーマシューティカルズ， インコーポレイテッド | アポリポタンパク質Ｅ（ＡｐｏＥ）ｉＲＮＡ剤組成物およびその使用方法 |
| MX2022013606A (es) | 2020-04-30 | 2023-01-16 | Alnylam Pharmaceuticals Inc | Composiciones de ácido ribonucleico interferente (arni) del factor b de complemento (cfb) y métodos de uso de las mismas. |
| WO2021237097A1 (en) | 2020-05-21 | 2021-11-25 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for inhibiting marc1 gene expression |
| CN116075592A (zh) | 2020-06-09 | 2023-05-05 | 阿尔尼拉姆医药品有限公司 | 用于沉默gpam(线粒体甘油-3-磷酸酰基转移酶1)表达的sirna组合物和方法 |
| WO2021252557A1 (en) | 2020-06-09 | 2021-12-16 | Alnylam Pharmaceuticals, Inc. | Rnai compositions and methods of use thereof for delivery by inhalation |
| AU2021292296A1 (en) | 2020-06-18 | 2023-01-19 | Alnylam Pharmaceuticals, Inc. | Xanthine dehydrogenase (XDH) iRNA compositions and methods of use thereof |
| US20230257745A1 (en) | 2020-07-10 | 2023-08-17 | Alnylam Pharmaceuticals, Inc. | Circular siRNAs |
| EP4217489A1 (de) | 2020-09-24 | 2023-08-02 | Alnylam Pharmaceuticals, Inc. | Dipeptidylpeptidase 4 (dpp4)-irna-zusammensetzungen und verfahren zur verwendung davon |
| EP4225917A1 (de) | 2020-10-05 | 2023-08-16 | Alnylam Pharmaceuticals, Inc. | G-protein-gekoppelter rezeptor-75 (gpr75)-irna-zusammensetzungen und verfahren zur verwendung davon |
| CA3198823A1 (en) | 2020-10-21 | 2022-04-28 | Alnylam Pharmaceuticals, Inc. | Methods and compositions for treating primary hyperoxaluria |
| EP4232582A1 (de) | 2020-10-23 | 2023-08-30 | Alnylam Pharmaceuticals, Inc. | Mucin-5b (muc5b)-irna-zusammensetzungen und verfahren zur verwendung davon |
| CA3200595A1 (en) | 2020-11-13 | 2022-05-19 | Alnylam Pharmaceuticals, Inc. | Coagulation factor v (f5) irna compositions and methods of use thereof |
| WO2022119873A1 (en) | 2020-12-01 | 2022-06-09 | Alnylam Pharmaceuticals, Inc. | Methods and compositions for inhibition of hao1 (hydroxyacid oxidase 1 (glycolate oxidase)) gene expression |
| WO2022125490A1 (en) | 2020-12-08 | 2022-06-16 | Alnylam Pharmaceuticals, Inc. | Coagulation factor x (f10) irna compositions and methods of use thereof |
| US20240336914A1 (en) | 2020-12-31 | 2024-10-10 | Alnylam Pharmaceuticals, Inc. | 2'-modified nucleoside based oligonucleotide prodrugs |
| US20240343746A1 (en) | 2020-12-31 | 2024-10-17 | Alnylam Pharmaceuticals, Inc. | Cyclic-disulfide modified phosphate based oligonucleotide prodrugs |
| EP4274896A1 (de) | 2021-01-05 | 2023-11-15 | Alnylam Pharmaceuticals, Inc. | Komplementkomponente 9 (c9)-irna-zusammensetzungen und verfahren zur verwendung davon |
| EP4291654A2 (de) | 2021-02-12 | 2023-12-20 | Alnylam Pharmaceuticals, Inc. | Superoxid-dismutase-1 (sod1)-irna-zusammensetzungen und verfahren zur verwendung davon zur behandlung oder vorbeugung von mit superoxid-dismutase 1 (sod1-) assoziierten neurodegenerativen erkrankungen |
| WO2022182864A1 (en) | 2021-02-25 | 2022-09-01 | Alnylam Pharmaceuticals, Inc. | Prion protein (prnp) irna compositions and methods and methods of use thereof |
| CA3211059A1 (en) | 2021-02-26 | 2022-09-01 | Alnylam Pharmaceuticals, Inc. | Ketohexokinase (khk) irna compositions and methods of use thereof |
| BR112023017737A2 (pt) | 2021-03-04 | 2023-10-03 | Alnylam Pharmaceuticals Inc | Composições de irna de angiopoietina-semelhantes 3 (angptl3) e métodos de uso das mesmas |
| EP4305169A1 (de) | 2021-03-12 | 2024-01-17 | Alnylam Pharmaceuticals, Inc. | Glykogensynthasekinase-3-alpha (gsk3a)-irna-zusammensetzungen und verfahren zur verwendung davon |
| BR112023019981A2 (pt) | 2021-03-29 | 2023-12-12 | Alnylam Pharmaceuticals Inc | Composições do agente irna de huntingtina (htt) e métodos de uso das mesmas |
| EP4314293A1 (de) | 2021-04-01 | 2024-02-07 | Alnylam Pharmaceuticals, Inc. | Prolindehydrogenase 2 (prodh2)-irna-zusammensetzungen und verfahren zur verwendung davon |
| CA3216106A1 (en) | 2021-04-26 | 2022-11-03 | Alnylam Pharmaceuticals, Inc. | Transmembrane protease, serine 6 (tmprss6) irna compositions and methods of use thereof |
| EP4330396A1 (de) | 2021-04-29 | 2024-03-06 | Alnylam Pharmaceuticals, Inc. | Signalwandler und aktivator von transkriptionsfaktor 6 (stat6)-irna-zusammensetzungen und verfahren zur verwendung davon |
| JP2024522068A (ja) | 2021-05-18 | 2024-06-11 | アルナイラム ファーマシューティカルズ， インコーポレイテッド | ナトリウム－グルコース共輸送体２（ｓｇｌｔ２）ｉｒｎａ組成物およびその使用方法 |
| MX2023014008A (es) | 2021-05-27 | 2023-12-11 | Alnylam Pharmaceuticals Inc | Composiciones y metodos para silenciar la expresion de anhidrasa carbonica 2. |
| WO2022256395A1 (en) | 2021-06-02 | 2022-12-08 | Alnylam Pharmaceuticals, Inc. | Patatin-like phospholipase domain containing 3 (pnpla3) irna compositions and methods of use thereof |
| MX2023014168A (es) | 2021-06-04 | 2024-02-27 | Alnylam Pharmaceuticals Inc | Marco de lectura abierto 72 del cromosoma humano 9 (c9orf72) composiciones de agente de arni y metodos de uso de este. |
| JP2024523000A (ja) | 2021-06-08 | 2024-06-25 | アルナイラム ファーマシューティカルズ， インコーポレイテッド | シュタルガルト病及び／又は網膜結合タンパク質４（ｒｂｐ４）関連障害を治療又は予防するための組成物及び方法 |
| IL309296A (en) | 2021-06-30 | 2024-02-01 | Alnylam Pharmaceuticals Inc | Methods and compositions for the treatment of angiotensinogen-related disorder (AGT-) |
| WO2023283403A2 (en) | 2021-07-09 | 2023-01-12 | Alnylam Pharmaceuticals, Inc. | Bis-rnai compounds for cns delivery |
| JP2024528659A (ja) | 2021-07-19 | 2024-07-30 | アルナイラム ファーマシューティカルズ， インコーポレイテッド | 非原発性高シュウ酸尿症疾患または障害を有するまたは発症するリスクがある対象を治療するための方法および組成物 |
| IL309897A (en) | 2021-07-21 | 2024-03-01 | Alnylam Pharmaceuticals Inc | Target gene IRNA compositions associated with a metabolic disorder and methods of using them |
| TW202325312A (zh) | 2021-07-23 | 2023-07-01 | 美商艾拉倫製藥股份有限公司 | β－鏈蛋白（ＣＴＮＮＢ１）ｉＲＮＡ組成物及其使用方法 |
| JP2024529437A (ja) | 2021-07-29 | 2024-08-06 | アルナイラム ファーマシューティカルズ， インコーポレイテッド | ３－ヒドロキシ－３－メチルグリタル－ＣＯＡレダクターゼ（ＨＭＧＣＲ）ｉＲＮＡ組成物およびその使用方法 |
| AR126675A1 (es) | 2021-08-03 | 2023-11-01 | Alnylam Pharmaceuticals Inc | COMPOSICIONES DE ARNi CONTRA LA TRANSTIRRETINA (TTR) Y SUS MÉTODOS DE USO |
| CA3228255A1 (en) | 2021-08-04 | 2023-02-09 | Alnylam Pharmaceuticals, Inc. | Irna compositions and methods for silencing angiotensinogen (agt) |
| CN118076737A (zh) | 2021-08-13 | 2024-05-24 | 阿尔尼拉姆医药品有限公司 | 因子XII（F12）iRNA组合物及其使用方法 |
| TW202325311A (zh) | 2021-08-31 | 2023-07-01 | 美商艾拉倫製藥公司 | 誘導細胞死亡之DFFA樣效應子B (CIDEB) iRNA組合物及其使用方法 |
| JP2024535850A (ja) | 2021-09-17 | 2024-10-02 | アルナイラム ファーマシューティカルズ， インコーポレイテッド | 補体成分（Ｃ３）をサイレンシングするためのｉＲＮＡ組成物および方法 |
| JP2024535888A (ja) | 2021-09-20 | 2024-10-02 | アルナイラム ファーマシューティカルズ， インコーポレイテッド | インヒビンサブユニットベータｅ（ｉｎｈｂｅ）モジュレーター組成物およびその使用方法 |
| KR20240067943A (ko) | 2021-09-24 | 2024-05-17 | 알닐람 파마슈티칼스 인코포레이티드 | 미소관 연관 단백질 타우(MAPT) iRNA 제제 조성물 및 이의 사용 방법 |
| EP4416284A1 (de) | 2021-10-15 | 2024-08-21 | Alnylam Pharmaceuticals, Inc. | Extrahepatische irna-zusammensetzungen zur abgabe und verfahren zur verwendung davon |
| AR127477A1 (es) | 2021-10-29 | 2024-01-31 | Alnylam Pharmaceuticals Inc | COMPOSICIONES DE ARNi CONTRA EL FACTOR B DEL COMPLEMENTO (CFB) Y MÉTODOS DE USO DE LAS MISMAS |
| EP4423272A2 (de) | 2021-10-29 | 2024-09-04 | Alnylam Pharmaceuticals, Inc. | Huntingtin (htt)-irna-wirkstoffzusammensetzungen und verfahren zur verwendung davon |
| EP4469575A2 (de) | 2022-01-24 | 2024-12-04 | Alnylam Pharmaceuticals, Inc. | Enzym-irna-wirkstoffzusammensetzungen für den heparinsulfatbiosyntheseweg und verfahren zur verwendung davon |
| EP4547683A2 (de) | 2022-06-30 | 2025-05-07 | Alnylam Pharmaceuticals, Inc. | Oligonukleotid-prodrugs auf basis von mit cyclischem disulfid modifiziertem phosphat |
| CN119907856A (zh) | 2022-09-15 | 2025-04-29 | 阿尔尼拉姆医药品有限公司 | 第13型17β-羟基类固醇脱氢酶(HSD17B13)iRNA组合物及其使用方法 |
| JP2025532985A (ja) | 2022-09-30 | 2025-10-03 | アルナイラム ファーマシューティカルズ， インコーポレイテッド | 修飾二本鎖ｒｎａ剤 |
| JP2026514045A (ja) | 2023-04-12 | 2026-05-01 | アルナイラム ファーマシューティカルズ， インコーポレイテッド | 二本鎖ｒｎａ剤の肝外デリバリー |
| EP4754255A1 (de) | 2023-08-04 | 2026-06-10 | Alnylam Pharmaceuticals, Inc. | Verfahren und zusammensetzungen zur behandlung von ctnnb1-assoziierten erkrankungen |
| WO2025064660A2 (en) | 2023-09-21 | 2025-03-27 | Alnylam Pharmaceuticals, Inc. | Activin a receptor type 1c (acvr1c) irna compositions and methods of use thereof |
| WO2025076031A2 (en) | 2023-10-03 | 2025-04-10 | Alnylam Pharmaceuticals, Inc. | Peritoneal macrophages comprising a nanoparticle encapsulating a nucleic acid molecule and methods of use thereof |
Family Cites Families (83)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0473576A4 (en) | 1989-05-19 | 1993-03-10 | Hem Research, Inc. | Short therapeutic dsrna of defined structure |
| US20030206887A1 (en) | 1992-05-14 | 2003-11-06 | David Morrissey | RNA interference mediated inhibition of hepatitis B virus (HBV) using short interfering nucleic acid (siNA) |
| WO1994001550A1 (en) | 1992-07-02 | 1994-01-20 | Hybridon, Inc. | Self-stabilized oligonucleotides as therapeutic agents |
| US6410322B1 (en) | 1993-07-27 | 2002-06-25 | Hybridon Inc | Antisense oligonucleotide inhibition of vascular endothelial growth factor expression |
| US5731294A (en) | 1993-07-27 | 1998-03-24 | Hybridon, Inc. | Inhibition of neovasularization using VEGF-specific oligonucleotides |
| US6060456A (en) | 1993-11-16 | 2000-05-09 | Genta Incorporated | Chimeric oligonucleoside compounds |
| US5587471A (en) | 1994-01-11 | 1996-12-24 | Isis Pharmaceuticals, Inc. | Method of making oligonucleotide libraries |
| JPH08208687A (ja) | 1994-11-25 | 1996-08-13 | Sankyo Co Ltd | グリセリルオリゴヌクレオチド |
| US6346398B1 (en) | 1995-10-26 | 2002-02-12 | Ribozyme Pharmaceuticals, Inc. | Method and reagent for the treatment of diseases or conditions related to levels of vascular endothelial growth factor receptor |
| US5998203A (en) * | 1996-04-16 | 1999-12-07 | Ribozyme Pharmaceuticals, Inc. | Enzymatic nucleic acids containing 5'-and/or 3'-cap structures |
| US6214805B1 (en) | 1996-02-15 | 2001-04-10 | The United States Of America As Represented By The Department Of Health And Human Services | RNase L activators and antisense oligonucleotides effective to treat RSV infections |
| US20040161844A1 (en) | 1996-06-06 | 2004-08-19 | Baker Brenda F. | Sugar and backbone-surrogate-containing oligomeric compounds and compositions for use in gene modulation |
| US5898031A (en) | 1996-06-06 | 1999-04-27 | Isis Pharmaceuticals, Inc. | Oligoribonucleotides for cleaving RNA |
| US20030064945A1 (en) | 1997-01-31 | 2003-04-03 | Saghir Akhtar | Enzymatic nucleic acid treatment of diseases or conditions related to levels of epidermal growth factor receptors |
| AU8525098A (en) | 1997-07-24 | 1999-02-16 | Inex Pharmaceuticals Corporation | Liposomal compositions for the delivery of nucleic acid catalysts |
| TW589189B (en) | 1997-08-04 | 2004-06-01 | Scras | Kit containing at least one double-stranded RNA combined with at least one anti-viral agent for therapeutic use in the treatment of a viral disease, notably of viral hepatitis |
| EP1015469B2 (de) | 1997-09-12 | 2015-11-18 | Exiqon A/S | Bi- und tri-zyklische - nukleosid, nukleotid und oligonukleotid-analoga |
| US6506559B1 (en) | 1997-12-23 | 2003-01-14 | Carnegie Institute Of Washington | Genetic inhibition by double-stranded RNA |
| CN101818145A (zh) | 1998-03-20 | 2010-09-01 | 联邦科学和工业研究组织 | 控制基因表达 |
| AUPP249298A0 (en) | 1998-03-20 | 1998-04-23 | Ag-Gene Australia Limited | Synthetic genes and genetic constructs comprising same I |
| DK1068311T3 (da) | 1998-04-08 | 2011-08-08 | Commw Scient Ind Res Org | Fremgangsmåder og midler til opnåelse af modificerede fænotyper |
| JP2002512794A (ja) | 1998-04-29 | 2002-05-08 | リボザイム・ファーマシューティカルズ・インコーポレーテッド | ヌクレオチド三リン酸およびリボザイム内へのそれらの取り込み |
| AR020078A1 (es) | 1998-05-26 | 2002-04-10 | Syngenta Participations Ag | Metodo para alterar la expresion de un gen objetivo en una celula de planta |
| GB9827152D0 (en) | 1998-07-03 | 1999-02-03 | Devgen Nv | Characterisation of gene function using double stranded rna inhibition |
| JP4841724B2 (ja) | 1998-10-09 | 2011-12-21 | ベジェニクス ピーティーワイ リミテッド | 腫瘍イメージングおよび抗腫瘍治療の標的としてのＦｌｔ４（ＶＥＲＧ−３） |
| AU776150B2 (en) | 1999-01-28 | 2004-08-26 | Medical College Of Georgia Research Institute, Inc. | Composition and method for (in vivo) and (in vitro) attenuation of gene expression using double stranded RNA |
| DE19956568A1 (de) | 1999-01-30 | 2000-08-17 | Roland Kreutzer | Verfahren und Medikament zur Hemmung der Expression eines vorgegebenen Gens |
| WO2000049035A1 (en) | 1999-02-19 | 2000-08-24 | The General Hospital Corporation | Gene silencing |
| US5998206A (en) | 1999-02-23 | 1999-12-07 | Isis Pharmaceuticals Inc. | Antisense inhibiton of human G-alpha-12 expression |
| US5998148A (en) | 1999-04-08 | 1999-12-07 | Isis Pharmaceuticals Inc. | Antisense modulation of microtubule-associated protein 4 expression |
| IL145778A0 (en) | 1999-04-21 | 2002-07-25 | American Home Prod | Methods and compositions for inhibiting the function of polynucleotide sequences |
| JP2003504061A (ja) | 1999-07-09 | 2003-02-04 | ワイス | プラスミド配列の転写の間における異常型ｒｎａの形成を防止するための方法および組成物 |
| EP1235842A4 (de) | 1999-10-15 | 2003-04-23 | Univ Massachusetts | Gene des rns-interferenzweges als hilfsmittel der gezielten gentischen interferenz |
| GB9927444D0 (en) | 1999-11-19 | 2000-01-19 | Cancer Res Campaign Tech | Inhibiting gene expression |
| DE10160151A1 (de) | 2001-01-09 | 2003-06-26 | Ribopharma Ag | Verfahren zur Hemmung der Expression eines vorgegebenen Zielgens |
| DE10100586C1 (de) | 2001-01-09 | 2002-04-11 | Ribopharma Ag | Verfahren zur Hemmung der Expression eines Ziegens |
| WO2001038551A1 (en) | 1999-11-29 | 2001-05-31 | Cold Spring Harbor Laboratory | Regulation of polycomb group gene expression for increasing seed size in plants |
| RU2164944C1 (ru) | 1999-12-09 | 2001-04-10 | Институт молекулярной биологии им. В.А. Энгельгардта РАН | Способ изменения генетических свойств организма |
| US20050229272A1 (en) | 1999-12-30 | 2005-10-13 | Monica Driscoll | Compositions and methods for gene silencing |
| IT1316982B1 (it) | 2000-01-17 | 2003-05-26 | Univ Roma | Isolamento e caratterizzazione di un gene per il silenziamento genicoda n.crassa e suoi usi. |
| US6602857B1 (en) | 2000-01-18 | 2003-08-05 | Isis Pharmaceuticals, Inc. | Antisense modulation of PTP1B expression |
| US6831171B2 (en) | 2000-02-08 | 2004-12-14 | Yale University | Nucleic acid catalysts with endonuclease activity |
| WO2003070918A2 (en) * | 2002-02-20 | 2003-08-28 | Ribozyme Pharmaceuticals, Incorporated | Rna interference by modified short interfering nucleic acid |
| JP2003526367A (ja) | 2000-03-16 | 2003-09-09 | ジェネティカ インコーポレイテッド | Ｒｎａ干渉の方法とｒｎａ干渉組成物 |
| CN1426466A (zh) | 2000-03-17 | 2003-06-25 | 贝尼泰克澳大利亚有限公司 | 遗传沉默 |
| EP1268535B1 (de) | 2000-03-22 | 2013-05-22 | Sanofi-Aventis Deutschland GmbH | Parkin aus c. elegans, nematode, der eine aberrante oder fehlende expression eines parkingens aufweist, und verwendungen davon |
| GB0007268D0 (en) | 2000-03-24 | 2000-05-17 | Cyclacel Ltd | Cell cycle progression proteins |
| KR20080023768A (ko) | 2000-03-30 | 2008-03-14 | 화이트헤드 인스티튜트 포 바이오메디칼 리서치 | Ｒｎａ 간섭의 ｒｎａ 서열 특이적인 매개체 |
| US6824972B2 (en) | 2000-05-22 | 2004-11-30 | Baylor College Of Medicine | Diagnosis and treatment of medical conditions associated with defective NFkappa B(NF-κB) activation |
| US20100305186A1 (en) | 2000-05-30 | 2010-12-02 | Johnson & Johnson Research Pty Limited | Methods for mediating gene suppression |
| WO2001096584A2 (en) | 2000-06-12 | 2001-12-20 | Akkadix Corporation | Materials and methods for the control of nematodes |
| PT1292335E (pt) | 2000-06-23 | 2007-08-13 | Bayer Schering Pharma Ag | Combinações e composições que interferem na função de receptores vegf/vegf e angiopoietina/ tie e a sua utilização (ii) |
| EP1311277A4 (de) | 2000-07-18 | 2004-08-25 | Joslin Diabetes Center Inc | Methoden zur fibrose-modulation |
| US20030190635A1 (en) | 2002-02-20 | 2003-10-09 | Mcswiggen James A. | RNA interference mediated treatment of Alzheimer's disease using short interfering RNA |
| US6613567B1 (en) | 2000-09-15 | 2003-09-02 | Isis Pharmaceuticals, Inc. | Antisense inhibition of Her-2 expression |
| AU2002224838B9 (en) | 2000-11-09 | 2007-02-08 | Cenix Bioscience Gmbh | Eukaryotic cell division genes and their use in diagnosis and treatment of proliferative diseases |
| CN100523215C (zh) | 2000-12-01 | 2009-08-05 | 马普科技促进协会 | 介导rna干涉的小rna分子 |
| EP1386004A4 (de) | 2001-04-05 | 2005-02-16 | Ribozyme Pharm Inc | Modulation der mit der entzündungsausbreitung und dem neuritenauswuchs assoziierten genexpression unter verwendung von technologien auf nukleinsäurebasis |
| EP1627061B1 (de) | 2001-05-18 | 2009-08-12 | Sirna Therapeutics, Inc. | Durch rna-interferenz vermittelte hemmung der genexpression unter verwendung von chemisch modifizierter sina (short interfering nucleic acid) |
| US20040019001A1 (en) | 2002-02-20 | 2004-01-29 | Mcswiggen James A. | RNA interference mediated inhibition of protein typrosine phosphatase-1B (PTP-1B) gene expression using short interfering RNA |
| WO2003070910A2 (en) | 2002-02-20 | 2003-08-28 | Ribozyme Pharmaceuticals, Incorporated | INHIBITION OF VASCULAR ENDOTHELIAL GROWTH FACTOR (VEGF) AND VEGF RECEPTOR GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA) |
| US20050148530A1 (en) * | 2002-02-20 | 2005-07-07 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of vascular endothelial growth factor and vascular endothelial growth factor receptor gene expression using short interfering nucleic acid (siNA) |
| WO2003070896A2 (en) | 2002-02-20 | 2003-08-28 | Sirna Therapeutics, Inc | RNA INTERFERENCE MEDIATED INHIBITION OF PROLIFERATING CELL NUCLEAR ANTIGEN (PCNA) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA) |
| PT2070939E (pt) * | 2001-05-25 | 2014-06-09 | Univ Duke | Moduladores de agentes farmacológicos |
| JP2005500025A (ja) | 2001-05-29 | 2005-01-06 | サーナ・セラピューティクス・インコーポレイテッド | 女性生殖疾病及び状態の核酸に基づく調節 |
| CA2457282C (en) | 2001-09-13 | 2015-01-13 | California Institute Of Technology | Method for expression of small antiviral rna molecules within a cell |
| KR100990055B1 (ko) | 2001-11-21 | 2010-10-26 | 사이고 가오루 | 유전자 발현 억제 방법 |
| EP1325955A1 (de) | 2002-01-04 | 2003-07-09 | atugen AG | Verbindungen und Verfahren zur Identifizierung und/oder Validierung eines Targets |
| EP1478656B1 (de) | 2002-02-01 | 2009-09-16 | Life Technologies Corporation | Oligonukleotidzusammensetzungen mit verbesserter effizienz |
| JP2005527198A (ja) | 2002-02-14 | 2005-09-15 | シティ・オブ・ホープ | 哺乳動物細胞において、干渉ｒｎａ分子を産生する方法、および該干渉ｒｎａ分子の療法的使用 |
| EP1432724A4 (de) | 2002-02-20 | 2006-02-01 | Sirna Therapeutics Inc | Durch rna-interferenz vermittelte inhibierung von map-kinase-genen |
| AU2003213054A1 (en) | 2002-02-20 | 2003-09-09 | Sirna Therapeutics, Inc. | RNA INTERFERENCE MEDIATED INHIBITION OF POLYCOMB GROUP PROTEIN EZH2 GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA) |
| US20040053876A1 (en) * | 2002-03-26 | 2004-03-18 | The Regents Of The University Of Michigan | siRNAs and uses therof |
| DK1490490T3 (da) | 2002-03-27 | 2009-09-07 | Aegera Therapeutics Inc | Antisense IAP--nukleobase-oligomerer og anvendelser deraf |
| ES2389024T3 (es) | 2002-08-05 | 2012-10-22 | Silence Therapeutics Aktiengesellschaft | Moléculas de RNA interferentes de extremos romos |
| WO2004029212A2 (en) | 2002-09-25 | 2004-04-08 | University Of Massachusetts | In vivo gene silencing by chemically modified and stable sirna |
| AU2003291682A1 (en) | 2002-11-05 | 2004-06-03 | Isis Pharmaceuticals, Inc. | 2'-methoxy substituted oligomeric compounds and compositions for use in gene modulations |
| JP3839453B2 (ja) | 2002-11-22 | 2006-11-01 | 株式会社バイオシンクタンク | Ｒｎａ干渉の標的塩基配列検索方法、ｒｎａ干渉を生じさせるポリヌクレオチドの塩基配列設計方法、２本鎖ポリヌクレオチドの作製方法、遺伝子の発現抑制方法、塩基配列処理装置、塩基配列処理方法をコンピュータに実行させるプログラム、記録媒体、および、塩基配列処理システム |
| AU2004210972A1 (en) | 2003-02-11 | 2004-08-26 | Immusol Incorporated | siRNA libraries optimized for predetermined protein families |
| EP1608733B1 (de) | 2003-04-02 | 2011-12-07 | Dharmacon, Inc. | Modifizierte polynukleotide zur verwendung bei rna-interferenz |
| WO2005049821A1 (ja) | 2003-11-21 | 2005-06-02 | Bio-Think Tank Co., Ltd. | ＲＮＡｉ活性およびｍｉＲＮＡ活性の評価方法 |
| US8685946B2 (en) | 2003-11-26 | 2014-04-01 | Universiy of Massachusetts | Sequence-specific inhibition of small RNA function |
| US20050182005A1 (en) | 2004-02-13 | 2005-08-18 | Tuschl Thomas H. | Anti-microRNA oligonucleotide molecules |
-
2005
- 2005-02-09 AT AT05713300T patent/ATE452188T1/de not_active IP Right Cessation
- 2005-02-09 EP EP05713300A patent/EP1713915B1/de not_active Expired - Lifetime
- 2005-02-09 AU AU2005212433A patent/AU2005212433B2/en not_active Expired
- 2005-02-09 CA CA002554212A patent/CA2554212A1/en not_active Abandoned
- 2005-02-09 WO PCT/US2005/004270 patent/WO2005078097A2/en not_active Ceased
- 2005-02-09 US US10/597,755 patent/US7858769B2/en not_active Expired - Lifetime
- 2005-02-09 JP JP2006553239A patent/JP2007523649A/ja not_active Withdrawn
-
2010
- 2010-11-16 US US12/947,609 patent/US20110118335A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| AU2005212433A1 (en) | 2005-08-25 |
| US7858769B2 (en) | 2010-12-28 |
| US20080039412A1 (en) | 2008-02-14 |
| US20110118335A1 (en) | 2011-05-19 |
| AU2005212433B2 (en) | 2010-12-16 |
| WO2005078097A3 (en) | 2005-10-27 |
| JP2007523649A (ja) | 2007-08-23 |
| EP1713915B1 (de) | 2009-12-16 |
| CA2554212A1 (en) | 2005-08-25 |
| WO2005078097A2 (en) | 2005-08-25 |
| EP1713915A2 (de) | 2006-10-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2005078097A3 (en) | RNA INTERFERENCE MEDIATED INHIBITION OF GENE EXPRESSION USING MULTIFUNCTIONAL SHORT INTERFERING NUCLEIC ACID (Multifunctional siNA) | |
| DK2287306T3 (da) | RNA interference mediated inhibition of gene expression using short interfering nucleic acid (siNA) | |
| WO2003070918A3 (en) | Rna interference by modified short interfering nucleic acid | |
| WO2003070884A3 (en) | RNA INTERFERENCE MEDIATED INHIBITION OF MDR P-GLYCOPROTEIN GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA) | |
| WO2005045034A3 (en) | RNA INTERFERENCE MEDIATED TREATMENT OF PARKINSON DISEASE USING SHORT INTERERING NUCLEIC ACID (siNA) | |
| WO2003070910A3 (en) | INHIBITION OF VASCULAR ENDOTHELIAL GROWTH FACTOR (VEGF) AND VEGF RECEPTOR GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA) | |
| WO2003070887A3 (en) | RNA INTERFERENCE MEDIATED INHIBITION OF POLYCOMB GROUP PROTEIN EZH2 GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA) | |
| WO2005084366A3 (en) | Transcription factor rna interference reagents and methods of use thereof | |
| EP1522583A3 (de) | Durch RNAi bewirkte Hemmung der Expression von dem Placental Growth Factor Gen mittels kleiner interfierender Nukleinsäuren (siNA) | |
| WO2003070197A3 (en) | RNA INTERFERENCE MEDIATED INHIBITION OF TGF-BETA AND TGF-BETA RECEPTOR GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA) | |
| EP1710307A3 (de) | Durch RNA-Interferenz vermittelte Hemmung der Genexpression unter Verwendung von siNA (short interfering nucleic acid) |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |